Cargando…

A new framework for evaluating the health impacts of treatment for Gaucher disease type 1

BACKGROUND: The Disease Severity Scoring System (DS3) is a validated measure for evaluating Gaucher disease type 1 (GD1) severity. We developed a new framework, consisting of health states, transition probabilities between those states, and preferences for those states (utilities) based on the DS3 t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ganz, Michael L., Stern, Sean, Ward, Alex, Nalysnyk, Luba, Selzer, Martin, Hamed, Alaa, Weinreb, Neal
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2017
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5319149/ https://www.ncbi.nlm.nih.gov/pubmed/28219443 http://dx.doi.org/10.1186/s13023-017-0592-6

Ejemplares similares

A health state utility valuation study to assess the impact of treatment mode of administration in Gaucher disease
por: Hadi, Monica, et al.
Publicado: (2018)

Budget Impact Analysis of Eliglustat for the Treatment of Gaucher Disease Type 1 in the United States
por: Nalysnyk, Luba, et al.
Publicado: (2018)

Cancer risk and gammopathies in 2123 adults with Gaucher disease type 1 in the International Gaucher Group Gaucher Registry
por: Rosenbloom, Barry E., et al.
Publicado: (2022)

The International Collaborative Gaucher Group GRAF (Gaucher Risk Assessment for Fracture) score: a composite risk score for assessing adult fracture risk in imiglucerase-treated Gaucher disease type 1 patients
por: Deegan, Patrick, et al.
Publicado: (2021)

Transformation in pretreatment manifestations of Gaucher disease type 1 during two decades of alglucerase/imiglucerase enzyme replacement therapy in the International Collaborative Gaucher Group (ICGG) Gaucher Registry
por: Mistry, Pramod K., et al.
Publicado: (2017)

Patients with type 1 Gaucher disease in South Florida, USA: demographics, genotypes, disease severity and treatment outcomes
por: Orenstein, Marissa, et al.
Publicado: (2014)

The Two Substrate Reduction Therapies for Type 1 Gaucher Disease Are Not Equivalent. Comment on Hughes et al. Switching between Enzyme Replacement Therapies and Substrate Reduction Therapies in Patients with Gaucher Disease: Data from the Gaucher Outcome Survey (GOS). J. Clin. Med. 2022, 11, 5158
por: Mistry, Pramod K., et al.
Publicado: (2023)

Gaucher Disease in Bone: From Pathophysiology to Practice
por: Hughes, Derralynn, et al.
Publicado: (2019)

Long-term clinical outcomes in type 1 Gaucher disease following 10 years of imiglucerase treatment
por: Weinreb, Neal J., et al.
Publicado: (2012)

Timing of initiation of enzyme replacement therapy after diagnosis of type 1 Gaucher disease: effect on incidence of avascular necrosis
por: Mistry, Pramod K, et al.
Publicado: (2009)

Evaluation of disease burden and response to treatment in adults with type 1 gaucher disease using a validated disease severity scoring system (DS3)
por: Weinreb, Neal J., et al.
Publicado: (2015)

Erratum to: Long-term clinical outcomes in type 1 Gaucher disease following 10 years of imiglucerase treatment
por: Weinreb, Neal J., et al.
Publicado: (2013)

Modeling potential interactions between oral Gaucher disease treatment and investigational COVID-19 therapies
por: Sahasrabudhe, Siddhee A., et al.
Publicado: (2021)

Lung transplantation in idiopathic pulmonary fibrosis: a systematic review of the literature
por: Kistler, Kristin D, et al.
Publicado: (2014)

Gaucher Disease and Gaucher Cells
por: Gözdaşoğlu, Sevgi
Publicado: (2015)

Patients with Gaucher disease display systemic oxidative stress dependent on therapy status
por: Kartha, Reena V., et al.
Publicado: (2020)

A multicenter open-label treatment protocol (HGT-GCB-058) of velaglucerase alfa enzyme replacement therapy in patients with Gaucher disease type 1: safety and tolerability
por: Pastores, Gregory M., et al.
Publicado: (2014)

Hepatocellular carcinoma in Gaucher disease: an international case series
por: Regenboog, Martine, et al.
Publicado: (2018)

Presenting signs and patient co‐variables in Gaucher disease: outcome of the Gaucher Earlier Diagnosis Consensus (GED‐C) Delphi initiative
por: Mehta, Atul, et al.
Publicado: (2019)

Impact and burden of acid sphingomyelinase deficiency from a patient and caregiver perspective
por: Pokrzywinski, Robin, et al.
Publicado: (2021)

Gaucher Cells or Pseudo-Gaucher Cells: That’s the Question
por: Gören Şahin, Deniz, et al.
Publicado: (2014)

Neuropathological Features of Gaucher Disease and Gaucher Disease with Parkinsonism
por: Furderer, Makaila L., et al.
Publicado: (2022)

Are There Neurological Symptoms in Type 1 of Gaucher Disease?
por: ALAEI, Mohammadreza, et al.
Publicado: (2018)

Type 3 Gaucher disease, diagnostic in adulthood
por: Detollenaere, Charles, et al.
Publicado: (2017)

A case of type-1 Gaucher disease
por: Raval, Helie P., et al.
Publicado: (2020)

Gaucher's disease
por: Bohra, Vijay, et al.
Publicado: (2011)

Gaucher’s Disease
Publicado: (1916)

COVID-19 patient impact: A survey of the Gaucher community involving patients, caregivers and family members based in the US to determine impact of the pandemic
por: Ryan, Emory, et al.
Publicado: (2021)

Characteristics of 26 patients with type 3 Gaucher disease: A descriptive analysis from the Gaucher Outcome Survey
por: Schwartz, Ida Vanessa D., et al.
Publicado: (2017)

Gaucher disease and SARS-CoV-2 infection: Emerging management challenges
por: Mistry, Pramod, et al.
Publicado: (2020)

Long-Term Evaluation of Biomarkers in the Czech Cohort of Gaucher Patients
por: Malinová, Věra, et al.
Publicado: (2023)

OnabotulinumtoxinA muscle injection patterns in adult spasticity: a systematic literature review
por: Nalysnyk, Luba, et al.
Publicado: (2013)

Development and validation of Gaucher disease type 1 (GD1)-specific patient-reported outcome measures (PROMs) for clinical monitoring and for clinical trials
por: Elstein, Deborah, et al.
Publicado: (2022)

The Saccadic and Neurological Deficits in Type 3 Gaucher Disease
por: Benko, William, et al.
Publicado: (2011)

Coxarthritis as the Presenting Symptom of Gaucher Disease Type 1
por: Brisca, Giacomo, et al.
Publicado: (2011)

The cognitive profile of type 1 Gaucher disease patients
por: Biegstraaten, Marieke, et al.
Publicado: (2012)

Neurocognitive profile of adults with the Norrbottnian type of Gaucher disease
por: Tsitsi, Panagiota, et al.
Publicado: (2021)

Retinal thinning in phenylketonuria and Gaucher disease type 3
por: Hopf, Susanne, et al.
Publicado: (2021)

Clinical response to eliglustat in treatment-naïve patients with Gaucher disease type 1: Post-hoc comparison to imiglucerase-treated patients enrolled in the International Collaborative Gaucher Group Gaucher Registry
por: Ibrahim, Jennifer, et al.
Publicado: (2016)

Gaucher Disease and the Synucleinopathies
por: Hruska, Kathleen S., et al.
Publicado: (2006)

Cannot write session to /tmp/vufind_sessions/sess_3j87q9l6e4sfmdr0p980o3ad7h